Cipla and DNDi announce the forthcoming launch of Artesunate + Mefloquine fixed-dose combination for P. falciparum malaria
Mumbai – Geneva, 24th April 2012: On the occasion of World Malaria Day, Cipla, one of the world’s leading generic pharmaceutical companies in collaboration with Drugs for Neglected Diseases Initiative (DNDi) announced the forthcoming launch of the Fixed-Dose combination of ‘Artesunate (AS)1 + Mefloquine (MQ)2’ for the treatment of uncomplicated P. falciparum malaria. There were an estimated 216 million cases of malaria globally in 2010. The combination of AS and MQ is proven to be a safe, rapid and…
